Close Menu

BGI

Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."

At the AGBT conference, MGI Tech showcased its technologies, while a Sanger Institute researcher presented results from a comparison between BGI and Illumina data.

The Shenzhen, China-based BGI subsidiary plans to expand its business to the United Arab Emirates, Qatar, Saudi Arabia, and other countries.

The effort, led by BGI-Shenzen researchers, could help further plant sequencing studies and inform upcoming large-scale plant sequencing plans.

CNGB was founded by the Chinese government and BGI to collect genomics technologies and resources, and promote their use by the research community.

The partners said they have agreed to work together on projects in a range of diseases, as well as establish research alliances with groups in China and Africa.

BGI was fined after found in 2015 to be conducting a genetics study illegally, according to the Global Times.

MGISEQ-T7

At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.

The companies will offer BGI's DNBseq next-generation sequencing technology along with Gencove's ImputeSeq low-pass sequencing analysis pipeline.

Researchers plan to sequence a hundred Pacific Northwest orcas to aid in their conservation, the Associated Press reports.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.